ArticleFrontiers in medicine2026
Construction of a safe and controllable quality management model for "Internet + Nursing Services" based on HFMEA strategy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop and evaluate a healthcare failure mode and effects analysis (HFMEA)-based quality management model for "Internet + Nursing Services" (INS) to enhance service safety, standardization, and stakeholder satisfaction, while assessing its economic impact. Methods: A retrospective controlled study was conducted. Patients receiving INS from January to December 2022 ( Results: The HFMEA-based model significantly improved safety and quality metrics. The adverse event incidence was reduced by 76.8% (1.50% in the experimental group vs. 6.47% in the control group, Conclusion: The HFMEA-based model was associated with a 76.8% reduction in adverse events, an 80% decrease in RPN, and improved satisfaction. However, causal conclusions are limited by the retrospective, single-center design. Preliminary cost savings were observed, but formal economic evaluation is needed. Replication in diverse settings and future multicenter studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.